Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate

Forrer, Flavio and Krenning, Eric P. and Kooij, Peter P. and Bernard, Bert F. and Konijnenberg, Mark and Bakker, Willem H. and Teunissen, Jaap J. M. and de Jong, Marion and van Lom, Kirsten and de Herder, Wouter W. and Kwekkeboom, Dik J.. (2009) Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate. European journal of nuclear medicine and molecular imaging, Vol. 36. pp. 1138-1146.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6005976

Downloads: Statistics Overview


Adequate dosimetry is mandatory for effective and safe peptide receptor radionuclide therapy (PRRT). Besides the kidneys, the bone marrow is a potentially dose-limiting organ. The radiation dose to the bone marrow is usually calculated according to the MIRD scheme, where the accumulated activity in the bone marrow is calculated from the accumulated radioactivity of the radiopharmaceutical in the blood. This may underestimate the absorbed dose since stem cells express somatostatin receptors. We verified the blood-based method by comparing the activity in the blood with the radioactivity in bone marrow aspirates. Also, we evaluated the absorbed cross-dose from the source organs (liver, spleen, kidneys and blood), tumours and the so-called "remainder of the body" to the bone marrow.
Faculties and Departments:03 Faculty of Medicine > Bereich Querschnittsfächer (Klinik) > Radiologie USB > Nuklearmedizin (Wild)
03 Faculty of Medicine > Departement Klinische Forschung > Bereich Querschnittsfächer (Klinik) > Radiologie USB > Nuklearmedizin (Wild)
UniBasel Contributors:Forrer, Flavio
Item Type:Article, refereed
Article Subtype:Research Article
Note:Publication type according to Uni Basel Research Database: Journal article
Last Modified:01 Feb 2013 08:46
Deposited On:01 Feb 2013 08:45

Repository Staff Only: item control page